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ABSTRACT
Objective Mesenteric fat hyperplasia is a hallmark of
Crohn’s disease (CD), and C reactive protein (CRP) is
correlated with disease activity. The authors investigated
whether mesenteric adipocytes may be a source of CRP
in CD and whether inﬂammatory and bacterial triggers
may stimulate its production by adipocytes.
Design CRP expression in the mesenteric and
subcutaneous fats of patients with CD and the
correlation between CRP plasma concentrations and
mesenteric messenger RNA (mRNA) levels were
assessed. The impact of inﬂammatory and bacterial
challenges on CRP synthesis was tested using an
adipocyte cell line. Bacterial translocation to mesenteric
fat was studied in experimental models of colitis and
ileitis and in patients with CD.
Results CRP expression was increased in the
mesenteric fat of patients with CD, with mRNA levels
being 80640 (p<0.05) and 140665 (p¼0.04) times
higher than in the mesenteric fat of patients with
ulcerative colitis and in the subcutaneous fat of the same
CD subjects, respectively, and correlated with plasma
levels. Escherichia coli (12306175-fold, p<0.01),
lipopolysaccharide (2660.5-fold, p<0.01), tumour
necrosis factor a (1560.3-fold, p<0.01) and
interleukin-6 (1060.7-fold, p<0.05) increased CRP
mRNA levels in adipocyte 3T3-L1 cells. Bacterial
translocation to mesenteric fat occurred in 13% and 27%
of healthy and CD subjects, respectively, and was
increased in experimental colitis and ileitis. Human
mesenteric adipocytes constitutively expressed mRNA
for TLR2, TLR4, NOD1 and NOD2.
Conclusion Mesenteric fat is an important source of
CRP in CD. CRP production by mesenteric adipocytes
may be triggered by local inﬂammation and bacterial
translocation to mesenteric fat, providing a mechanism
whereby mesenteric fat hyperplasia may contribute to
inﬂammatory response in CD.
INTRODUCTION
C reactive protein (CRP) was ﬁrst discovered in
1930 in the serum of patients with pneumonia.
1 Its
name was derived from its ability to react to the
cell wall C polypeptide of Streptococcus pneumoniae.
1
For over 75 years, CRP has been extensively used in
the clinic as a non-speciﬁc systemic marker of
inﬂammation
2 and is considered as one of the most
important biomarkers in Crohn’s disease (CD).
High serum concentrations of CRP in CD have
been associated with poor prognosis,
3 a high
response rate to anti-tumour necrosis factor (TNF)
treatment
4 and an increased risk of relapse
following withdrawal of medical therapies.
5
Mesenteric fat hyperplasia is a characteristic
feature of CD that is not found in ulcerative colitis
(UC).
6 While the liver has long been considered as
the unique source of CRP,
2 recent evidence indicates
that adipocytes may represent an extrahepatic
source of CRP in humans.
7 Body mass index has
been correlated with plasma CRP levels in obese
patients.
8 Increased mesenteric fat density evalu-
ated by CT enterography was found to correlate
with serum CRP levels in patients with CD.
9
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Signiﬁcance of this study
What is already known on this subject?
< Mesenteric fat hyperplasia is a characteristic
feature of Crohn’s disease (CD).
< Adipocytes are an extrahepatic source of C
reactive protein (CRP) in humans.
< Increased mesenteric fat density correlates with
serum CRP levels in CD.
What are the new ﬁndings?
< Mesenteric fat is an important source of CRP in
CD.
< CRP production by mesenteric adipocytes is
triggered by inﬂammatory and bacterial stimuli.
< Bacterial translocation to mesenteric adipocytes
occurs at a rate similar to that for the
translocation of mesenteric lymph nodes in CD.
How might it impact on clinical practice in the
foreseeable future?
< These data further establish the role of adipose
tissue as a contributor to inﬂammatory response
in CD and provide a rationale for targeting
mesenteric fat in the treatment of this chronic
disorder.
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Inﬂammatory bowel diseaseThe regulatory mechanisms of CRP synthesis by the liver
include interleukin (IL)-6 as a potent inducer of its expression in
humans.
10 TNFa and IL-6 are the main pro-inﬂammatory
cytokines secreted by the adipose tissue, suggesting that local
inﬂammation within mesenteric fat may contribute to increased
levels of CRP in CD.
11 Furthermore, CD is characterised by
increased intestinal permeability and bacterial translocation,
12
and fat cells are able to respond to bacterial components.
13
Recent studies have demonstrated that adipocytes can respond
to bacterial challenge by constitutively expressing a broad set of
pattern recognition molecules (PRMs), including Toll-like
receptors (TLRs) 1e11, nucleotide oligomerisation domain
(NOD) 1 and NOD2.
13e16 We thus speculated that an increased
cytokine production in the inﬂamed mesentery, together with
translocating bacteria, may trigger CRP production by mesenteric
adipocytes in CD and contribute to its elevated serum levels.
The aims of this study were therefore to investigate the
production of CRP by mesenteric adipocytes in patients with
CD and in controls and to assess in vitro and in vivo the effects
of inﬂammatory and bacterial stimuli on CRP synthesis by
adipocytes.
MATERIALS AND METHODS
See supplemental material.
Patients and controls
Twenty-two patients with CD (mean age at the time of surgery:
32 years; male patients¼14; pure ileal disease¼11; ileocolonic
disease¼10; pure colonic disease¼1; non-stricturing non-pene-
trating phenotype¼7; structuring phenotype¼12; penetrating
phenotype¼3; perianal disease¼6; patients on azathioprine at
the time of surgery ¼9), 17 patients with UC (mean age at the
time of surgery: 42 years; male patients¼7; patients on azathi-
oprine at the time of surgery ¼5) and 21 controls (19 patients
with colorectal neoplasia and 2 patients operated on for diver-
ticulitis) who underwent surgery were prospectively included.
All patients from the ‘diverticulitis’ group were operated on
a few weeks after experiencing diverticulitis, and all adipose
tissue biopsies were taken away from inﬂammatory lesions.
All patients gave written informed consent, and the study
protocol was approved by the local committee. The diagnosis
of CD or UC was based on the usual criteria.
17 All subjects
were of normal weight (deﬁned as 20 kg/m
2<body mass
index<5 kg/m
2), had no personal history of diabetes mellitus
and were not being treated with speciﬁc medications known to
modulate visceral fat (inﬂiximab, steroids and metformin
18).
Patients with CD underwent right ileocolectomy for symp-
tomatic ileal stenosis or ﬁstula. Patients with UC underwent
colonic resection for disease refractory to standard treatment.
Subcutaneous/mesenteric fat specimens were taken during surgery,
and ileal and colonic transparietal biopsies were performed.
Ethical guidelines in studies on humans were followed under the
supervision of an investigator, and human samples were declared
to Inserm according to French laws (articles L. 1243-3 and
R. 1243-49, and the Code de la Santé Publique).
Adipose tissues and intestinal specimen
Specimens of mesenteric and subcutaneous adipose tissues,
healthy and inﬂamed colonic samples, and healthy and
inﬂamed terminal ileal samples were taken during surgery.
Histological evaluation was performed to conﬁrm the absence
of inﬂammation on intestinal biopsies and to select fat speci-
mens at a distance from mesenteric lymph nodes. Intestinal
biopsies were immediately frozen in liquid nitrogen and stored
at  808C for messenger RNA (mRNA) and protein analyses.
Three samples of mesenteric and subcutaneous fats were
collected. One sample was ﬁxed in 4% paraformaldehyde/
phosphate-buffered formalin and embedded in parafﬁnf o r
immunostaining. The second sample was immediately frozen
in liquid nitrogen and stored at  808C for mRNA and protein
analyses. The third sample was taken under sterile conditions at
the time of surgery and placed in normal saline for a short-term
culture.
3T3-L1 cells
3T3-L1 pre-adipocytes (ATCC CL-173) were grown to conﬂu-
ence in Dulbecco’sm o d i ﬁed Eagle’sm e d i u m( D M E M ;G i b c o
Invitrogen, Grand Island, New York, USA) with 10% fetal calf
serum (Eurobio, Paris, France) and penicillin and streptomycin
(Gibco). The medium was supplemented with 1 M dexameth-
asone (Merck, Darmstadt, Germany), 0.2 mM isobutyl methyl
xanthine (Gibco), 10 g/ml insulin (Actrapid; NovoNordisk,
Bagsvaerd, Denmark) and 10% fetal calf serum (Eurobio) for
48 h.
19 Cell viability was conﬁrmed by testing lactate dehy-
drogenase activity in the culture medium taken during the
course of the differentiation process or on mature 3T3-L1 cells.
Adipogenesis was conﬁrmed by staining fat droplets with oil
red O (Acros Organics, Geel, Belgium), which made lipid
accumulation visible (the hallmark of adipogenic conversion),
and by measuring the synthesis of aP2 mRNA, an adipocyte-
speciﬁc gene and well-established marker for terminal adipocyte
differentiation.
Cytokine and bacterial challenge
To investigate the regulation of CRP expression in vitro, we
stimulated differentiated 3T3-L1 cells with optimal concen-
trations of recombinant TNFa (50 ng/ml) or IL-6 (10 ng/ml)
20
(Sigma-Aldrich, St Quentin Fallavier, France), lipopolysac-
charide (LPS) (100 ng/ml; Invitrogen, Villebon sur Yvette,
France), lipopeptide Pam3Cys (1 mg/ml) or muramyl dipeptide
(10 mg/ml; Calbiochem, Fontenay sous bois, France) for 3, 6, 9,
12 or 24 h.
19e21 3T3-L1 cells were also infected with Escherichia
coli previously isolated from the mesenteric fat biopsy speci-
mens of a CD patient or with Lactobacillus spp. (infectivity
ratio: 100 bacteria/cell) for 90 min. Cell viability was assessed
at the end of infection before cell washing in 1.0 ml of sterile
phosphate-buffered saline and treatment with DMEM with
gentamicin (10 mg/ml; Gibco) for 24 h.
CRP release in short-term cultures of human adipose tissue
Short-term cultures were prepared with surgical specimens to
examine the release of CRP from mesenteric and subcutaneous
fats, as previously described.
22 Brieﬂy, adipose tissue samples
were diced ﬁnely into 1e2 mm pieces (150 mg, wet weight) and
washed twice in Hanks’ balanced salt solution containing 0.2%
bovine serum albumin. Samples were placed in sterile tissue
culture plates containing 2 ml of DMEM supplemented with
10% fetal bovine serum and antibiotics (penicillin and strepto-
mycin) at 378C under an atmosphere of air/CO2 (95:5, vol/vol)
for 24 h. CRP concentration in the cultured adipose tissue
supernatant was determined by enzyme-linked immunosorbent
assay (R&D Systems, UK).
Determination of blood CRP concentrations
Blood samples were collected 1 day before surgery. Serum CRP
was quantiﬁed using a highly sensitive immunoassay
(Cortecnet, Paris, France).
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lymph nodes
Human samples
During surgery, mesenteric lymph nodes and mesenteric adipose
tissue samples were immediately introduced in 8 ml of pre-
weighed cysteinated 1/4 strength Ringer solution containing
0.5% Tween 80 (Flandre-Chimie, Villeneuve d’Ascq, France). The
samples were transported to the laboratory within 2 h and
treated immediately, weight was established and tissues were
disrupted. Five milliliters of the suspension was inoculated in
100 ml ﬂasks containing cysteinated braineheart enrichment
broth (detection level at about 2 bacteria/g), and 1 ml was
inoculated in 10 ml of the same broth (detection level at about
10 bacteria/g). Enrichment broths were incubated under anaer-
obic conditions for 10 days, with regular checking of growth.
About 0.1 ml of the samples was placed on two plates of
Columbia blood agar: one plate was incubated under aerobic
conditions for 48 h, and the second plate was incubated under
anaerobic conditions for 7 days. Two further 10-fold dilutions
were plated in the same manner. Positive enrichment broths
were subcultured on anaerobic Columbia blood agar plates.
23
Animal samples
Mesenteric lymph nodes and mesenteric adipose tissue samples
were immediately introduced in 1.5 ml of cysteinated 1/4
strength Ringer solution in pre-weighed tubes. Weight was
established, and samples were disrupted. One milliliter of the
suspension was introduced in 10 ml of cysteinated braineheart
enrichment broth (detection level at about 100 bacteria/g).
About 0.1 ml was plated on Columbia blood agar and incubated
for 7 days under anaerobic conditions. Subcultures were
obtained as described above.
23 All animal studies were approved
by the local investigational review board. Animal experiments
were performed in an accredited establishment (no. B59-35009)
according to governmental guidelines (no. 86/609/CEE) under
the supervision of an authorised investigator (no. 59-350191).
Statistical analysis
All results are expressed as mean6SEM and analysed by non-
parametric ManneWhitney U test or KruskaleWallis test.
Paired comparisons were analysed by Wilcoxon matched pairs
test. Pearson’s correlation coefﬁcient (r) was used to evaluate
associations between two variables. Fisher’s exact test was used
to analyse categorical data when sample sizes were small.
Differences were judged as statistically signiﬁcant if the p value
was less than 0.05.
RESULTS
CRP is overexpressed in CD mesenteric adipose tissue
With real-time PCR, CRP mRNA was detected in all tissues
analysed, that is, in ileal and colonic samples, as well as in
mesenteric and subcutaneous adipose tissues. We ﬁrst compared
the expressions of CRP in adipose tissues taken from UC, CD
and control subjects (ﬁgure 1A). The CRP gene was overex-
pressed in the mesenteric fat of patients with CD (n¼6), with
mRNA levels being 80640 and 14506750 times higher than
those detected in the mesenteric fat of UC individuals (n¼6;
p<0.05 vs CD) and controls (n¼4; p<0.01 versus CD), respec-
tively (ﬁgure 1A). The mRNA levels of CRP within the mesen-
teric fat of patients with UC were not statistically different
from controls (ﬁgure 1A). Of note, expression levels of CRP were
similar in the ‘diverticulitis’ group and the ‘colorectal neoplasia’
group (data not shown). No statistical difference in CRP mRNA
transcripts was seen in subcutaneous fat between patients with
CD, patients with UC and controls (data not shown).
To further examine the overexpression of CRP in mesenteric
adipose tissues in CD, we compared paired CRP mRNA levels in
Figure 1 Overexpression of CRP
mRNA and protein in mesenteric fat in
CD. (A) Comparison of CRP expressions
measured by real-time PCR in the
mesenteric fat of patients with CD,
patients with UC and control
individuals. Signiﬁcantly higher levels of
CRP transcript levels were found in
patients with CD compared to patients
with UC and controls. Results are
expressed as mean6SEM. (B) CRP
mRNA levels in samples of mesenteric
adipose tissue (Mes.) and
subcutaneous fat (S/c) taken from the
same patients with CD (n¼6), patients
with UC (n¼3) or patients without IBD
(n¼3). Unlike in UC and control
subjects in whom CRP mRNA levels are
similar in mesenteric and subcutaneous
fats, the CRP gene is overexpressed in
mesenteric fat compared to
subcutaneous fat in patients with CD.
Median values are indicated by the
horizontal line. (C) Expression of CRP
gene in human mesenteric (Mes.) and
subcutaneous (S/c) fat samples and in
biopsy specimens of macroscopically
and histologically healthy ileum (Ile.) or
healthy colon (Col.) obtained from six UC, six CD and four control subjects using real-time PCR. Compared with adipose tissues, a modest (colon) or
a weak (ileum) expression of CRP mRNA was observed in intestinal wall samples obtained from patients with UC, patients with CD or controls. Results
are expressed as mean6SEM. CD, Crohn’s disease; UC, ulcerative colitis; IBD, inﬂammatory bowel disease.
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Inﬂammatory bowel diseasesubcutaneous and mesenteric fats in the same patients (ﬁgure
1B). In patients with CD, median CRP mRNA levels in
mesenteric adipose tissue were 140665 times higher than those
in the subcutaneous adipose tissue of the same CD subjects
(p¼0.04). In contrast to CD, CRP mRNA levels were broadly
similar in subcutaneous and mesenteric adipose tissues in
patients with UC and controls (ﬁgure 1B).
To determine whether the intestine that is adjacent to
mesenteric fat may be another signiﬁcant local source of CRP
in CD, we compared intestinal (small intestine and colon) and
adipose tissue CRP mRNA levels. CRP mRNA levels in
mesenteric or subcutaneous adipose tissue in the 10 patients
without CD (UC, n¼6; controls, n¼4) were 150690 times
higher than those detected in the intestinal wall of the same
patients (p<0.05) (ﬁgure 1C). Due in part to mesenteric fat
hyperplasia, CRP mRNA levels in the mesenteric adipose tissue
of patients with CD (n¼6) were higher (217500667500
times) than those detected in the intestinal wall of the same
patients (p<0.01) (ﬁgure 1C). Of note, low and broadly similar
CRP mRNA levels were detected in inﬂamed or healthy
intestine (colon or small bowel) in patients with CD and
patients with UC (data not shown), indicating that the
enhanced CRP levels in active CD do not come directly from
the intestinal wall.
We next investigated CRP expression at the protein level to
demonstrate that mesenteric adipocytes may be the main local
source of plasma CRP in CD. The overexpression of CRP was
conﬁrmed at the protein level by western blot analysis using
mesenteric adipose tissue explants (ﬁgure 2A); the median CRP/
b-actin ratio was 0.01, 2.55 and 0.29 in controls, patients with
CD and patients with UC, respectively (ﬁgure 2B).
Collectively, these ﬁndings indicate that mesenteric adipose
tissue is an important source of CRP in patients with CD.
CRP is released by mesenteric adipose tissue
To investigate whether mesenteric CRP overexpression may be
a potential source of CRP in the serum of patients with CD, we
evaluated the ability of mesenteric adipose tissue to release CRP
and compared CRP mesenteric expression level with plasma
CRP level in paired samples of patients with CD.
The release of CRP was detected at levels superior to 1 pg/ml
in all culture media collected after a 24 h short-term culture of
subcutaneous and mesenteric adipose tissue specimens taken
from patients with inﬂammatory bowel disease (IBD) and
controls (data not shown). Plasma CRP concentrations were
positively correlated with mesenteric CRP transcript levels
(r¼0.79, p¼0.05) in the six patients with CD (ﬁgure 2C),
whereas no correlation was observed in UC and control subjects
(data not show). Plasma CRP levels were not correlated with the
intestinal mRNA levels of CRP in UC, CD and control subjects
(data not shown).
Taken together, these results suggest that CRP released by
mesenteric fat may be responsible, at least in part, for elevated
plasma CRP levels in patients with CD.
CRP expression is enhanced by inﬂammatory and bacterial
stimuli
To better understand the mechanisms that trigger CRP expres-
sion by adipocytes, we measured CRP mRNA levels according to
the differentiation and activation states of adipocytes.
A2 1 62.5-fold induction of CRP mRNA expression was
observed during the differentiation of 3T3-L1 pre-adipocytes
into adipocytes (p<0.05 vs pre-adipocytes) (ﬁgure 2D). The
aP2 mRNA level (a well-established marker of terminal adipo-
cyte differentiation) parallelled the increase in CRP mRNA,
indicating that CRP expression is dependent on adipocyte
differentiation (ﬁgure 2D).
Figure 2 CRP expression by human
mesenteric fat and correlation between
mesenteric and plasma CRP
concentrations in CD. (A) Levels of CRP
by western blot analysis of mesenteric
adipose tissue from one control patient
who was operated on for colorectal
cancer (Ctrl), CD subjects and UC
subjects. Actin protein levels were
determined to verify equal loading of
samples. (B) The median CRP/b-actin
ratio by western blot analysis is 0.01,
2.55 and 0.29 in controls (n¼4),
patients with CD (n¼5) and patients
with UC (n¼4), respectively. (C)
Correlation between plasma CRP
concentrations measured at surgery
and CRP mRNA levels quantiﬁed by
real-time PCR in mesenteric adipose
tissues taken during surgery from six
patients with CD. (D) CRP mRNA levels
parallel with and aP2 mRNA expression
during the 9 days of 3T3-L1 pre-
adipocyte differentiation into adipocytes
on the indicated days. Results are
expressed as fold induction as
compared with undifferentiated pre-
adipocytes (mean6SEM of three
experiments). CD, Crohn’s disease;
UC, ulcerative colitis.
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Inﬂammatory bowel diseaseTNFa and IL-6 are the two main pro-inﬂammatory cytokines
secreted by adipose tissue.
6 With the use of differentiated 3T3-L1
adipocytes, treatment with TNFa and IL-6 resulted in a 1560.3-
fold and 1060.7-fold increase in CRP mRNA expression,
respectively (ﬁgure 3A).
Since CD is characterised by increased bacterial translocation,
12
we next tested the hypothesis that bacterial components may
stimulate CRP synthesis by adipocytes. We ﬁrst measured the
capacity of pre-adipocytes and differentiated adipocytes to
express CRP after Ec o l ichallenge (ﬁgure 3B). While bacterial
infection strongly enhanced CRP mRNA expression in adipocytes
(22906700-fold induction over unstimulated cells), the CRP gene
expression in pre-adipocytes was only modestly promoted by the
same bacterial challenge (120642-fold induction, p<0.05 vs
adipocytes at 12 h) (ﬁgure 3B).
E coli infection induced a rapid and dramatic 12306175-fold
increase in CRP mRNA levels, which reached its maximum at
9 h after bacterial infection (ﬁgure 3C). Similarly, stimulation of
adipocytes with LPS, a structural component of the outer wall
of Gram-negative bacteria and a TLR4 ligand, led to a marked
and sustained elevation (2660.5-fold induction and p<0.01 over
unstimulated adipocytes) in CRP mRNA levels, which paral-
lelled that of adipocytes challenged with E coli. By contrast,
stimulation with lipopeptide Pam3Cys (a TLR2 ligand) or
muramyl dipeptide (a NOD2 ligand) had a modest effect or no
effect on CRP expression in 3T3-L1 adipocytes, respectively
(ﬁgure 3C). As controls, 3T3-L1 cells were stimulated with
a non-pathogenic Gram-positive Lactobacillus strain, which was
not able to signiﬁcantly enhance CRP synthesis by adipocytes
(ﬁgure 3C).
Because mesenteric adipocytes might be concomitantly
exposed to both inﬂammatory and bacterial compounds, we
next investigated the effects of such stimuli when administered
separately or successively. The increase in CRP mRNA levels
following challenge with E coli (96620-fold induction over
unstimulated cells) was higher when compared to treatment
with TNFa (3862-fold induction over unstimulated cells)
(ﬁgure 3D). Interestingly, 3 h after the end of bacterial infection,
the production of CRP in TNFa pre-treated 3T3-L1 cells was
enhanced synergistically by the addition of E coli (5276104-fold
induction over unstimulated cells), as shown in ﬁgure 3D.
Overall, CRP biogenesis in adipocytes is strongly inducible
by Gram-negative bacteria and enhanced synergistically by pro-
inﬂammatory cytokines.
Bacterial translocation to mesenteric adipocytes is increased
during experimental colitis
Since we have shown that bacterial challenge was able to
increase CRP synthesis by adipocytes in vitro, we next explored
whether bacterial translocation occurred in mesenteric lymph
nodes and directly in adipocytes of mesenteric tissue. Bacterial
translocation is classically deﬁned as the passage of viable
bacteria from the gastrointestinal tract to mesenteric lymph
nodes and then to peripheral organs such as the liver and
spleen.
24 Thus, in all animal experiments, the rate of bacterial
translocation to mesenteric lymph nodes was used as an internal
control.
The induction of dextran sulfate sodium (DSS) colitis was
conﬁrmed macroscopically and histologically, as previously
described.
25 Bacterial translocation to mesenteric adipocytes
occurred spontaneously in 15% of control mice (n¼20) and was
signiﬁcantly enhanced in 100% of animals with DSS-induced
colitis (n¼8, p¼0.0001) (ﬁgure 4A). Similarly, signiﬁcantly
higher rates of bacterial translocation to mesenteric lymph
nodes were noted in animals receiving 2% DSS (n¼8) when
compared to control mice (87.5% vs 5%, p¼0.0001). The rates of
bacterial translocation were broadly similar in mesenteric
adipose tissue and mesenteric lymph nodes (100% vs 87.5%,
Figure 3 Induction of CRP expression
in 3T3-L1 adipocytes following cytokine
and/or bacterial challenge. (A)
Differentiated 3T3-L1 adipocytes were
stimulated with 10 ng/ml IL-6 or 50 ng/
ml TNFa for 24 h. (B) Ability of 3T3-L1
pre-adipocytes and adipocytes to
respond to the same bacterial
challenge. Cells were infected with
a strain of E coli isolated from a CD
patient at a multiplicity of 100 pfu/cell
for 1 h 30 min. Induction of CRP mRNA
expression was then followed over
time. (C) Differentiated 3T3-L1
adipocytes were infected with E coli or
Lactobacillus spp. (infectivity ratio, 100
bacteria/cell) for 1 h 30 min, or treated
with 100 ng/ml LPS, 1 mg/ml Pam3Cys
or 10 mg/ml muramyl dipeptide for 24 h.
(D) Synergistic effect of bacterial and
cytokine stimuli on CRP expression in
differentiated 3T3-L1 adipocytes. Cells
were pre-treated with 50 ng/ml TNFa
for 24 h before infection with E coli
(infectivity ratio, 100 bacteria/cell). CRP
mRNA expression was measured at 3 h
after bacterial infection. In all
experiments described in this ﬁgure,
total RNA was isolated from 3T3-L1 cells at the indicated times, and levels of CRP mRNA were determined by real-time PCR. Results are expressed as
the mean6SEM of three independent experiments and fold induction as compared with unstimulated adipocytes. IL, interleukin; LPS,
lipopolysaccharide.
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Inﬂammatory bowel diseasep¼NS) in DSS-treated mice, as well as in control animals (15%
vs 5%, p¼NS) (ﬁgure 4A).
Bacterial translocation to mesenteric adipocytes is increased
during experimental ileitis
Bacterial translocation may require a bacterial load of >10
8
organisms per milliliter of faeces.
26 Therefore, it is usually
assumed that the colon is the main site of bacterial trans-
location. We thus investigated whether bacterial translocation to
mesenteric fat and lymph nodes may also occur in an experi-
mental model of ileitis. The induction of indomethacin-induced
ileitis was conﬁrmed macroscopically and histologically, as
previously described.
27 Bacterial translocation to mesenteric
adipose tissue occurred in 80% of indomethacin-treated rats
(n¼15) compared with 11% of control rats (n¼9) (p¼0.002)
(ﬁgure 4B). Higher rates of bacterial translocation to mesenteric
lymph nodes were also noted in rats following intraperitoneal
administration of indomethacin when compared to control
animals (67% vs 22%, p¼0.089). The rates of bacterial trans-
location were broadly similar in mesenteric adipose tissue and
mesenteric lymph nodes (80% vs 67%, p¼NS) in indomethacin-
treated rats, as well as in control animals (11% vs 22%, p¼NS)
(ﬁgure 4B).
Bacterial translocation to mesenteric adipocytes that
constitutively express PRMs in humans
We then investigated whether bacterial translocation to
mesenteric adipocytes may occur in patients with CD. Consis-
tent with our results in animals, the rate of bacterial trans-
location to mesenteric adipose tissue was similar to that
observed in mesenteric lymph nodes in the 22 patients with CD
(27% and 23%, respectively, p¼NS) (ﬁgure 4C). When compared
to control and UC subjects (n¼38), the rate of bacterial trans-
location to mesenteric adipose tissue was higher in the 22
patients with CD, but the difference did not reach statistical
signiﬁcance (13% vs 27%, p¼0.198). In line with previous
reports,
12 the rate of bacterial translocation to mesenteric lymph
nodes was also higher in CD individuals than in non-CD indi-
viduals (control and UC individuals), even though the difference
did not reach statistical signiﬁcance (23% vs 8%, respectively,
p¼0.129) (ﬁgure 4C). Of note, rates of bacterial translocation did
not differ between UC and control subjects, and the results in
patients with CD were not inﬂuenced by disease behaviour or
disease location according to the Montreal classiﬁcation.
28
Consistent with previous reports,
14 16 29 human mesenteric
adipocytes from control subjects were found to constitutively
express a wide range of PRMs, namely TLR2, TLR4, NOD1 and
NOD2, at the transcriptional level, thus conﬁrming that
mesenteric fat cells can respond to bacterial challenge (web
ﬁgure 1). Similar mRNA expression levels of TLR2, TLR4, NOD1
and NOD2 were noted in controls, patients with UC and
patients with CD (data not shown).
Collectively, our results demonstrate that bacterial trans-
location to mesenteric adipocytes expressing PRMs occurs
physiologically at a rate similar to that of mesenteric lymph
nodes in both animals and patients with CD.
DISCUSSION
We identiﬁed mesenteric and subcutaneous adipose tissues as
sources of CRP in humans at both RNA and protein levels. CRP
mRNA and protein were overexpressed in mesenteric fat
compared to the subcutaneous adipose tissue of patients with
CD. A 140-fold increase in mesenteric CRPexpression was noted
when comparing the mesenteric and subcutaneous fats of the
same CD subjects at the transcriptional level. In addition, a 105-
fold higher expression of CRP was observed when comparing the
mesenteric fats of CD and control subjects. These ﬁndings
unravel a dysregulation of CRP expression that is conﬁned to
mesenteric fat in CD. These results are in line with a previous
report in patients with other chronic inﬂammatory diseases.
30
Of note, this overexpression may have been underestimated in
our study, as all real-time PCR results were normalised to the
Figure 4 Bacterial translocation to
mesenteric adipose tissue following
acute DSS-induced colitis in mice,
acute indomethacin-induced ileitis in
rats and bacterial translocation in
humans. (A) Rates of bacterial
translocation (BT) to mesenteric
adipose tissue (MAT) and mesenteric
lymph nodes (MLN) in C57BL/6 mice
with acute colitis induced by 2% DSS
for 5 days and killed after 2 days on day
7( n ¼8) and in control animals (n¼20).
(B) Rates of bacterial translocation (BT)
to mesenteric adipose tissue (MAT) and
mesenteric lymph nodes (MLN) in rats
with acute ileitis induced by
indomethacin (n¼15) and in control
animals (n¼9). (C) Rates of bacterial
translocation (BT) to mesenteric
adipose tissue (MAT) and mesenteric
lymph nodes (MLN) in patients without
CD (controls and patients with UC,
n¼38) and patients with CD (n¼22).
UC, ulcerative colitis; DSS, dextran
sulfate sodium.
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Inﬂammatory bowel diseaseunaffected housekeeping gene b-actin while hyperplasia of
mesenteric adipose tissue is present in CD.
11 Indeed, the
abdominal fat area in CD is composed of a global 4-fold increase
in the number of adipocytes as compared to controls, which is
related to a reduced size of adipocytes in CD.
6 To our knowledge,
only one study investigated the expression of CRP in animals.
31
In this study, the authors demonstrated for the ﬁrst time that
CRP is expressed by white adipose tissue in mice.
31 However,
data on an animal model of IBD are not available.
Mucosal lesions on endoscopy are not well correlated to
plasma CRP levels in CD,
32 suggesting that the intestine may
not be the only source of CRP. Indeed, CRP mRNA transcripts
were detectable in the intestinal wall of controls, but at much
lower levels than in mesenteric fat. Furthermore, this expression
was similar in the healthy and inﬂamed intestines, as well as in
patients with CD and patients without CD. Overall, these
results indicate that inﬂammation of the mesentery, resulting in
increased CRP production by adipocytes, may be a prominent
locoregional source of CRP in patients with CD. We cannot
exclude that the liver is a signiﬁcant source of plasma CRP in
CD. A portal venous puncture or liver biopsydan invasive
procedure that we decided to avoid in these patients for ethical
reasonsdmay have been performed to address this issue.
To investigate the regulatory mechanisms of CRP production
by adipocytes, we analysed the response of differentiated 3T3-L1
adipocytes to cytokine stimuli. IL-6 is recognised as a potent
inducer of CRP production by hepatocytes
10 33 and adipocytes.
7
Studies using IL-6-deﬁcient mice have demonstrated that IL-6,
although necessary, is not sufﬁcient for induced expression of
the CRP transgene, and have suggested that other regulators of
CRP production exist.
34 We found that CRP synthesis was
inducible by IL-6 stimulation in vitro. IL-6 produced by the liver
may thus contribute to enhancement of CRP synthesis by
adipocytes in vivo. We also identiﬁed TNFa as a possible inducer
of CRP expression in the mouse cell line 3T3-L1. These results
should be interpreted with caution, since incubation of human
adipose explants with TNFa was shown to have only a minor
effect on CRP expression.
7 Nevertheless, such discrepancy may
be explained by a dose-dependent response, as Anty et al
7
used TNFa at a lower dosage than in our experiments (20 vs
50 ng/ml, respectively).
CD is characterised by increased bacterial translocation.
12 Our
results showing that LPS and E coli markedly induced the
production of CRP by differentiated 3T3-L1 adipocytes led us to
investigate whether bacterial translocation may occur through
mesenteric adipose tissue. We demonstrated that mesenteric fat
is a new site of bacterial translocation in humans. This
phenomenon occurred spontaneously in 13% of healthy subjects
at a rate broadly similar to that of mesenteric lymph nodes.
Furthermore, bacterial translocation to mesenteric adipose tissue
was observed in 27% of patients with CD also at a rate broadly
similar to that of mesenteric lymph nodes. TLR1e11, NOD1
and NOD2 are known to be constitutively expressed in murine
pre-adipocytes and adipocytes
16 35 and, interestingly, bacterial
translocation to mesenteric fat was increased in experimental
models of colitis. DSS is known to cause UC-like disease in mice.
Using an experimental model of ileitis, we also found an
increased bacterial translocation in these animals. Here, we
conﬁrmed that human mesenteric adipocytes also constitutively
express a wide range of PRMs, including TLR4, indicating that
these fat cells are capable of sensing Gram-negative bacteria.
Collectively, the present data show that CRP biogenesis in
adipose tissues may be preferentially triggered by TLR4 ligand,
especially Gram-negative bacteria that translocate from the
bowel lumen. Adenovirus-36 was shown to enhance the differ-
entiation of pre-adipocytes in 3T3-L1 cells and increased
adiposity in experimentally infected animals.
36 The responsive-
ness of adipocytes to translocating bacteria may thus contribute
to mesenteric fat hypertrophy in CD.
13 We also found that
TNFa synergistically enhanced the effect of a bacterial stimulus
on adipocyte CRP expression. By stimulating the production of
IL-6, TNFa may further enhance the production of CRP in CD.
7
Local cytokine production and translocation of Gram-negative
bacteria may thus synergise to promote CRP biogenesis by
mesenteric adipocytes in CD.
In conclusion, our data further conﬁrm that mesenteric fat is
not an innocent bystander and may contribute to inﬂammatory
response in patients with CD.
37 Whether mesenteric fat has
a protective role by killing translocating bacteria will require
further investigation.
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